SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT.

The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Silinda Neou
Nurix Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.